The Quantellect read.As of Nov 19, 2026, 17 active firms cover Bristol-Myers Squibb Company: 8 rate it Buy or better, 8 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets range widely, $41.00 to $82.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $65.29 sits 12% above the current $58.35. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.52 next quarter toward $6.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 active firms
Neutral
Strong Buy00%
Buy847%
Neutral847%
Sell16%
Strong Sell00%
Based on 17 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$65.29
+11.9% upside
Average target across 17 active firms as of Nov 19, 2026 vs $58.35 current
Highest Target$82.00
Average Target$65.29
Lowest Target$41.00
Detailed analyst forecasts for BMY
Showing 1–18 of 18 named analysts shown · 17 active firms in the rating projection
As of Nov 19, 2026, 8 of 17 active firms rate BMY a Buy (8 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BMY EPS & revenue forecast
EPS · NEXT QUARTER
$1.52
Range $1.31 – $1.68 · 9 analysts · -4% YoY
Next period, 9 analysts expect Bristol-Myers Squibb Company to earn $1.52 a share (range $1.31 – $1.68), versus $1.58 a year earlier. Full-year consensus is $6.44, growing to $6.70 the year after.
REVENUE · NEXT QUARTER
$11.2B
Range $10.6B – $11.4B · 9 analysts · -3% YoY
Revenue is expected to reach $11.2B (range $10.6B – $11.4B), -2.8% year-over-year. Full-year consensus is $50.2B, rising to $48.8B next year.
Top analysts covering Bristol-Myers Squibb Company
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BMY.
#1
David Amsellem
Piper Sandler · Rank #124
Buy
$78.00+33.7% to target
Overall win rate
50%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #160
Buy
$67.00+14.8% to target
Overall win rate
47%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Sell
$41.00-29.7% to target
Overall win rate
36%
+ Follow
#4
CS
Chris Schott
JP Morgan · Rank #287
Buy
$73.00+25.1% to target
Overall win rate
41%
+ Follow
#5
Carter Gould
Cantor Fitzgerald
Neutral
$53.00-9.2% to target
Coverage
—
+ Follow
BMY stock forecast FAQ
What is BMY's average 12-month price target?+
The 17 active firms with a live target average $65.29 for Bristol-Myers Squibb Company over the next 12 months, ranging from a $82.00 high to a $41.00 low, as of Nov 19, 2026.
Is BMY stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 17 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 8 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BMY?+
The Street-high target is $82.00 (Piper Sandler), and the Street-low is $41.00 (Morgan Stanley). The average of all 17 active-firm targets is $65.29.
How many active Wall Street firms cover BMY?+
17 active firms have a recognized rating on Bristol-Myers Squibb Company as of Nov 19, 2026, and 17 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BMY?+
Among analysts who currently cover BMY, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #124). Their current call is Buy with a $78.00 target.
What is Bristol-Myers Squibb Company's projected EPS for next quarter?+
The consensus estimate is $1.52 per share (range $1.31 – $1.68) across 9 analysts. Full-year EPS is projected at $6.44, rising to $6.70 the following year.
How much revenue is Bristol-Myers Squibb Company expected to report next quarter?+
Consensus revenue is $11.2B (range $10.6B – $11.4B). Full-year revenue is projected at $50.2B, growing to $48.8B next year.
Have analysts been upgrading or downgrading BMY lately?+
As of Nov 19, 2026, 8 of 17 active firms rate BMY a Buy (8 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BMY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.